136 related articles for article (PubMed ID: 28404374)
1. Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
Martínez González S; Rodríguez-Arístegui S; Hernández AI; Varela C; González Cantalapiedra E; Álvarez RM; Rodríguez Hergueta A; Bischoff JR; Albarrán MI; Cebriá A; Cendón E; Cebrián D; Alfonso P; Pastor J
Bioorg Med Chem Lett; 2017 Jun; 27(11):2536-2543. PubMed ID: 28404374
[TBL] [Abstract][Full Text] [Related]
2. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Martínez González S; Hernández AI; Álvarez RM; Rodríguez A; Ramos-Lima F; Bischoff JR; Albarrán MI; Cebriá A; Hernández-Encinas E; García-Arocha J; Cebrián D; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2017 Nov; 27(21):4794-4799. PubMed ID: 29017786
[TBL] [Abstract][Full Text] [Related]
4. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
5. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
9. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Lorenzo M; Rodríguez A; Rivero V; Martín JI; Saluste CG; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán M; Alfonso P; García-Serelde B; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Pastor J
Bioorg Med Chem Lett; 2012 May; 22(10):3460-6. PubMed ID: 22520259
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
[TBL] [Abstract][Full Text] [Related]
11. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
12. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
13. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
14. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
15. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
[TBL] [Abstract][Full Text] [Related]
16. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
[TBL] [Abstract][Full Text] [Related]
17. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.
Tardy S; Orsato A; Mologni L; Bisson WH; Donadoni C; Gambacorti-Passerini C; Scapozza L; Gueyrard D; Goekjian PG
Bioorg Med Chem; 2014 Feb; 22(4):1303-12. PubMed ID: 24468632
[TBL] [Abstract][Full Text] [Related]
20. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
